Individualization of Treatment in T2DM Patients with CVD

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Individualization of Treatment in T2DM Patients with CVD

By Cardiometabolic Health Congress (CMHC) FEATURING Harold Bays

527 views

October 22, 2019

1 Comment

Chest Pain in Women: CT's role in making an accurate diagnosis

Feat. L. Shaw, M. Gulati

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

The Protein Myth: Our Obsession With Protein and How It Is Killing US

Feat. G. Davis

64:45

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi

12:04

Stephen Kopecky

Role of PCSK9 Inhibitors in Diabetes

11:37

ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich

28:13

National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

Feat. R. Mason

11:25

ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster

17:21

Ilene Fennoy

Obesity and Diabetes in Children

18:43

ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo

15:06

Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01

Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo

12:26

Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

15:33

Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44

Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24

Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan

26:32

Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen

20:24

Diana Isaacs

Tirzepatide for Type 2 Diabetes

63:46

University of Louisville

Management of Cushing's Disease: Striving for Personalized Care

Feat. M. Fleseriu

31:46

ACC 2024 Insights

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

Feat. M. Costanzo

26:49

Diana Isaacs

Tirzepatide Updates

28:02

Barbara Mcgowan

Login

Login

Join VuMedi

Individualization of Treatment in T2DM Patients with CVD

Related Content